Anti-hepatitis C virus E2 (HCV/E2) glycoprotein monoclonal antibodies and neutralization interference

Antiviral Research

Volumn 96, Issue 1, 2012, Pages 82-89

  Sautto, Giuseppe ^a   Mancini, Nicasio ^a   Diotti, Roberta A ^a   Solforosi, Laura ^a   Clementi, Massimo ^a   Burioni, Roberto ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Hepatitis C virus; Interfering antibody; Monoclonal antibody; Neutralizing antibody

Indexed keywords

ANTIHEPATITIS C VIRUS E2 GLYCOPROTEIN MONOCLONAL ANTIBODY; EPITOPE; HEPATITIS C ANTIBODY; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; HEPATITIS C; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; VIRUS INTERFERENCE; VIRUS NEUTRALIZATION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; EPITOPES, B-LYMPHOCYTE; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HUMANS; NEUTRALIZATION TESTS; VIRAL ENVELOPE PROTEINS;

HEPATITIS C VIRUS;

EID: 84865477865     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2012.07.013     Document Type: Article

References (49)

1. Alter M.J., Margolis H.S., Krawczynski K., Judson F.N., Mares A., Alexander W.J., Hu P.Y., Miller J.K., Gerber M.A., Sampliner R.E., et al. The natural history of community-acquired hepatitis C in the United States. The sentinel counties chronic non-A, non-B hepatitis study team. N. Engl. J. Med. 1992, 327:1899-1905.
2. Angus A.G., Patel A.H. Immunotherapeutic potential of neutralizing antibodies targeting conserved regions of the HCV envelope glycoprotein E2. Future Microbiol. 2011, 6:279-294.
3. Armstrong G.L., Wasley A., Simard E.P., McQuillan G.M., Kuhnert W.L., Alter M.J. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann. Intern. Med. 2006, 144:705-714.
4. Broering T.J., Garrity K.A., Boatright N.K., Sloan S.E., Sandor F., Thomas W.D., Szabo G., Finberg R.W., Ambrosino D.M., Babcock G.J. Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus. J. Virol. 2009, 83:12473-12482.
5. Brown R.S. Hepatitis C and liver transplantation. Nature 2005, 436:973-978.
6. Bugli F., Mancini N., Kang C.Y., Di Campli C., Grieco A., Manzin A., Gabrielli A., Gasbarrini A., Fadda G., Varaldo P.E., Clementi M., Burioni R. Mapping B-cell epitopes of hepatitis C virus E2 glycoprotein using human monoclonal antibodies from phage display libraries. J. Virol. 2001, 75:9986-9990.
7. Burioni R., Bugli F., Mancini N., Rosa D., Di Campli C., Moroncini G., Manzin A., Abrignani S., Varaldo P.E., Clementi M., Fadda G. Nonneutralizing human antibody fragments against hepatitis C virus E2 glycoprotein modulate neutralization of binding activity of human recombinant Fabs. Virology 2001, 288:29-35.
8. Burioni R., Matsuura Y., Mancini N., Tani H., Miyamura T., Varaldo P.E., Clementi M. Diverging effects of human recombinant anti-hepatitis C virus (HCV) antibody fragments derived from a single patient on the infectivity of a vesicular stomatitis virus/HCV pseudotype. J. Virol. 2002, 76:11775-11779.
9. Burioni R., Perotti M., Mancini N., Clementi M. Perspectives for the utilization of neutralizing human monoclonal antibodies as anti-HCV drugs. J. Hepatol. 2008, 49:299-300.
10. Burioni R., Plaisant P., Manzin A., Rosa D., Delli Carri V., Bugli F., Solforosi L., Abrignani S., Varaldo P.E., Fadda G., Clementi M. Dissection of human humoral immune response against hepatitis C virus E2 glycoprotein by repertoire cloning and generation of recombinant Fab fragments. Hepatology 1998, 28:810-814.
11. Clayton R.F., Owsianka A., Aitken J., Graham S., Bhella D., Patel A.H. Analysis of antigenicity and topology of E2 glycoprotein present on recombinant hepatitis C virus-like particles. J. Virol. 2002, 76:7672-7682.
12. Clementi N., De Marco D., Mancini N., Solforosi L., Moreno G.J., Gubareva L.V., Mishin V., Di Pietro A., Vicenzi E., Siccardi A.G., Clementi M., Burioni R. A human monoclonal antibody with neutralizing activity against highly divergent influenza subtypes. PLoS ONE 2011, 6:e28001.
13. De Marco D., Clementi N., Mancini N., Solforosi L., Moreno G.J., Sun X., Tumpey T.M., Gubareva L.V., Mishin V., Clementi M., Burioni R. A non-VH1-69 heterosubtypic neutralizing human monoclonal antibody protects mice against H1N1 and H5N1 viruses. PLoS ONE 2012, 7:e34415.
14. Di Lorenzo C., Angus A.G.N., Patel A.H. Hepatitis C virus evasion mechanisms from neutralizing antibodies. Viruses 2011, 3:2280-2300.
15. Drummer H.E., Boo I., Maerz A.L., Poumbourios P. A conserved Gly436-Trp-Leu-Ala-Gly-Leu-Phe-Tyr motif in hepatitis C virus glycoprotein E2 is a determinant of CD81 binding and viral entry. J. Virol. 2006, 80:7844-7853.
16. Edwards V.C., Tarr A.W., Urbanowicz R.A., Ball J.K. The role of neutralizing antibodies in hepatitis C virus infection. J. Gen. Virol. 2012, 93:1-19.
17. El Abd Y.S., Tabll A.A., El Din N.G., Hosny Ael D., Moustafa R.I., El-Shenawy R., Atef K., El-Awady M.K. Neutralizing activities of caprine antibodies towards conserved regions of the HCV envelope glycoprotein E2. Virol. J. 2011, 8:391.
18. Farci P., Alter H.J., Wong D.C., Miller R.H., Govindarajan S., Engle R., Shapiro M., Purcell R.H. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc. Natl. Acad. Sci. USA 1994, 91:7792-7796.
19. Flint M., Thomas J.M., Maidens C.M., Shotton C., Levy S., Barclay W.S., McKeating J.A. Functional analysis of cell surface-expressed hepatitis C virus E2 glycoprotein. J. Virol. 1999, 73:6782-6790.
20. Gottwein J.M., Scheel T.K., Jensen T.B., Lademann J.B., Prentoe J.C., Knudsen M.L., Hoegh A.M., Bukh J. Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology 2009, 49:364-377.
21. Johansson D.X., Voisset C., Tarr A.W., Aung M., Ball J.K., Dubuisson J., Persson M.A. Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus. Proc. Natl. Acad. Sci. USA 2007, 104:16269-16274.
22. Keck Z.Y., Li T.K., Xia J., Gal-Tanamy M., Olson O., Li S.H., Patel A.H., Ball J.K., Lemon S.M., Foung S.K. Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies. J. Virol. 2008, 82:6061-6066.
23. Keck Z.Y., Op De Beeck A., Hadlock K.G., Xia J., Li T.K., Dubuisson J., Foung S.K. Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions. J. Virol. 2004, 78:9224-9232.
24. Keck Z.Y., Xia J., Wang Y., Wang W., Krey T., Prentoe J., Carlsen T., Li A.Y., Patel A.H., Lemon S.M., Bukh J., Rey F.A., Foung S.K. Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV e2 with resistance to neutralization escape in a genotype 2a isolate. PLoS Pathog. 2012, 8:e1002653.
25. Krey T., d'Alayer J., Kikuti C.M., Saulnier A., Damier-Piolle L., Petitpas I., Johansson D.X., Tawar R.G., Baron B., Robert B., England P., Persson M.A., Martin A., Rey F.A. The disulfide bonds in glycoprotein E2 of hepatitis C virus reveal the tertiary organization of the molecule. PLoS Pathog. 2010, 6:e1000762.
26. Lapierre P., Troesch M., Alvarez F., Soudeyns H. Structural basis for broad neutralization of hepatitis C virus quasispecies. PLoS ONE 2011, 6:e26981.
27. Law M., Maruyama T., Lewis J., Giang E., Tarr A.W., Stamataki Z., Gastaminza P., Chisari F.V., Jones I.M., Fox R.I., Ball J.K., McKeating J.A., Kneteman N.M., Burton D.R. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat. Med. 2008, 14:25-27.
28. Lesniewski R.R., Watanabe S., Devare S.G. Expression of HCV envelope proteins and the serological utility of the anti-E2 immune response. Princess Takamatsu Symp. 1995, 25:129-137.
29. Lindenbach B.D., Evans M.J., Syder A.J., Wolk B., Tellinghuisen T.L., Liu C.C., Maruyama T., Hynes R.O., Burton D.R., McKeating J.A., Rice C.M. Complete replication of hepatitis C virus in cell culture. Science 2005, 309:623-626.
30. Makris M., Preston F.E., Rosendaal F.R., Underwood J.C., Rice K.M., Triger D.R. The natural history of chronic hepatitis C in haemophiliacs. Br. J. Haematol. 1996, 94:746-752.
31. Mancini N., Diotti R.A., Perotti M., Sautto G., Clementi N., Nitti G., Patel A.H., Ball J.K., Clementi M., Burioni R. Hepatitis C virus (HCV) infection may elicit neutralizing antibodies targeting epitopes conserved in all viral genotypes. PLoS ONE 2009, 4:e8254.
32. Martell M., Esteban J.I., Quer J., Genesca J., Weiner A., Esteban R., Guardia J., Gomez J. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J. Virol. 1992, 66:3225-3229.
33. Matthews D.J., Williams D.G., Patel A.H. Hepatitis C virus antibodies. United States Patent Application 2011, 2011(0002926):A1.
34. Meyer K., Banerjee A., Frey S.E., Belshe R.B., Ray R. A weak neutralizing antibody response to hepatitis C virus envelope glycoprotein enhances virus infection. PLoS ONE 2011, 6:e23699.
35. Owsianka A., Tarr A.W., Juttla V.S., Lavillette D., Bartosch B., Cosset F.L., Ball J.K., Patel A.H. Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J. Virol. 2005, 79:11095-11104.
36. Owsianka A.M., Tarr A.W., Keck Z.Y., Li T.K., Witteveldt J., Adair R., Foung S.K., Ball J.K., Patel A.H. Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein. J. Gen. Virol. 2008, 89:653-659.
37. Owsianka A.M., Timms J.M., Tarr A.W., Brown R.J., Hickling T.P., Szwejk A., Bienkowska-Szewczyk K., Thomson B.J., Patel A.H., Ball J.K. Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding. J. Virol. 2006, 80:8695-8704.
38. Perotti M., Mancini N., Diotti R.A., Tarr A.W., Ball J.K., Owsianka A., Adair R., Patel A.H., Clementi M., Burioni R. Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein. J. Virol. 2008, 82:1047-1052.
39. Pestka J.M., Zeisel M.B., Blaser E., Schurmann P., Bartosch B., Cosset F.L., Patel A.H., Meisel H., Baumert J., Viazov S., Rispeter K., Blum H.E., Roggendorf M., Baumert T.F. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc. Natl. Acad. Sci. USA 2007, 104:6025-6030.
40. Pietschmann T., Kaul A., Koutsoudakis G., Shavinskaya A., Kallis S., Steinmann E., Abid K., Negro F., Dreux M., Cosset F.L., Bartenschlager R. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc. Natl. Acad. Sci. USA 2006, 103:7408-7413.
41. Raghava G.P., Agrewala J.N. Method for determining the affinity of monoclonal antibody using non-competitive ELISA: a computer program. J. Immunoassay 1994, 15:115-128.
42. Sabo M.C., Luca V.C., Prentoe J., Hopcraft S.E., Blight K.J., Yi M., Lemon S.M., Ball J.K., Bukh J., Evans M.J., Fremont D.H., Diamond M.S. Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step. J. Virol. 2011, 85:7005-7019.
43. Simmonds P., Bukh J., Combet C., Deleage G., Enomoto N., Feinstone S., Halfon P., Inchauspe G., Kuiken C., Maertens G., Mizokami M., Murphy D.G., Okamoto H., Pawlotsky J.M., Penin F., Sablon E., Shin I.T., Stuyver L.J., Thiel H.J., Viazov S., Weiner A.J., Widell A. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005, 42:962-973.
44. Sullivan N.J. Antibody-mediated enhancement of viral disease. Curr. Top. Microbiol. Immunol. 2001, 260:145-169.
45. Tarr A.W., Owsianka A.M., Timms J.M., McClure C.P., Brown R.J., Hickling T.P., Pietschmann T., Bartenschlager R., Patel A.H., Ball J.K. Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. Hepatology 2006, 43:592-601.
46. Tarr A.W., Urbanowicz R.A., Jayaraj D., Brown R.J., McKeating J.A., Irving W.L., Ball J.K. Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization. J. Virol. 2011, 86:2739-2749.
47. Troesch M., Meunier I., Lapierre P., Lapointe N., Alvarez F., Boucher M., Soudeyns H. Study of a novel hypervariable region in hepatitis C virus (HCV) E2 envelope glycoprotein. Virology 2006, 352:357-367.
48. Wakita T., Pietschmann T., Kato T., Date T., Miyamoto M., Zhao Z., Murthy K., Habermann A., Krausslich H.G., Mizokami M., Bartenschlager R., Liang T.J. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 2005, 11:791-796.
49. Zhang P., Zhong L., Struble E.B., Watanabe H., Kachko A., Mihalik K., Virata-Theimer M.L., Alter H.J., Feinstone S., Major M. Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity. Proc. Natl. Acad. Sci. USA 2009, 106:7537-7541.